Ocugen Inc. [NASDAQ: OCGN] gained 6.33% or 0.14 points to close at $2.35 with a heavy trading volume of 5744040 shares. The company report on September 6, 2022 that Ocugen, Inc. to Present at H.C. Wainwright 24th Annual Global Investment Conference.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will participate in an in-person fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022 in New York, NY.
It opened the trading session at $2.25, the shares rose to $2.35 and dropped to $2.20, the range by which the price of stock traded the whole day. The daily chart for OCGN points out that the company has recorded -3.69% loss over the past six months. However, it is still -40.72% lower than its most recent low trading price.
If we look at the average trading volume of 5.74M shares, OCGN reached to a volume of 5744040 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Ocugen Inc. [OCGN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for OCGN shares is $7.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on OCGN stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Mizuho have made an estimate for Ocugen Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 23, 2022. While these analysts kept the previous recommendation, ROTH Capital raised their target price to Buy. The new note on the price target was released on June 15, 2022, representing the official price target for Ocugen Inc. stock. Previously, the target price had yet another raise to $4.50, while Cantor Fitzgerald analysts kept a Overweight rating on OCGN stock.
The Average True Range (ATR) for Ocugen Inc. is set at 0.19 The Price to Book ratio for the last quarter was 4.43, with the Price to Cash per share for the same quarter was set at 0.49.
Trading performance analysis for OCGN stock
Ocugen Inc. [OCGN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.20. With this latest performance, OCGN shares dropped by -17.54% in over the last four-week period, additionally sinking by -3.69% over the last 6 months – not to mention a drop of -67.85% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for OCGN stock in for the last two-week period is set at 42.94, with the RSI for the last a single of trading hit 40.22, and the three-weeks RSI is set at 45.06 for Ocugen Inc. [OCGN]. The present Moving Average for the last 50 days of trading for this stock 2.61, while it was recorded at 2.43 for the last single week of trading, and 3.28 for the last 200 days.
Ocugen Inc. [OCGN]: A deeper dive into fundamental analysis
Ocugen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.90 and a Current Ratio set at 11.90.
An analysis of insider ownership at Ocugen Inc. [OCGN]
There are presently around $200 million, or 39.70% of OCGN stock, in the hands of institutional investors. The top three institutional holders of OCGN stocks are: STATE STREET CORP with ownership of 30,617,946, which is approximately 5.022% of the company’s market cap and around 0.40% of the total institutional ownership; BLACKROCK INC., holding 13,777,504 shares of the stock with an approximate value of $32.38 million in OCGN stocks shares; and VANGUARD GROUP INC, currently with $26.83 million in OCGN stock with ownership of nearly 4.687% of the company’s market capitalization.
65 institutional holders increased their position in Ocugen Inc. [NASDAQ:OCGN] by around 9,906,628 shares. Additionally, 53 investors decreased positions by around 9,043,174 shares, while 23 investors held positions by with 66,213,556 shares. The mentioned changes placed institutional holdings at 85,163,358 shares, according to the latest SEC report filing. OCGN stock had 24 new institutional investments in for a total of 1,877,410 shares, while 21 institutional investors sold positions of 3,326,337 shares during the same period.